GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » K Pharma Inc (TSE:4896) » Definitions » Net Income From Continuing Operations

K Pharma (TSE:4896) Net Income From Continuing Operations : 円-233 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is K Pharma Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. K Pharma's net income from continuing operations for the three months ended in Mar. 2024 was 円-233 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was 円-233 Mil.

K Pharma Net Income From Continuing Operations Historical Data

The historical data trend for K Pharma's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

K Pharma Net Income From Continuing Operations Chart

K Pharma Annual Data
Trend Dec21 Dec22 Dec23
Net Income From Continuing Operations
-229.12 -390.53 301.08

K Pharma Quarterly Data
Dec21 Dec22 Jun23 Sep23 Dec23 Mar24
Net Income From Continuing Operations Get a 7-Day Free Trial - - - - -233.45

K Pharma Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-233 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

K Pharma (TSE:4896) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » K Pharma Inc (TSE:4896) » Definitions » Net Income From Continuing Operations
Comparable Companies
TSE:7776 TSE:4888 TSE:4594 TSE:4598 TSE:4588 TSE:4891 TSE:2370 TSE:3750 TSE:4583 TSE:4564 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
7-7-7 Roppongi, Minato-ku, Tokyo, JPN, 106-0032
Website
https://en.kpharma.co.jp
K Pharma Inc is a company involved in Research, development, manufacturing, sales and marketing of pharmaceutical products and regenerative medicine products. It is involved in studying of iPs cells in regnerative medecine to treat neurological conditions such as cerebral infarction and SCI.

K Pharma (TSE:4896) Headlines

No Headlines